The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.46 (-5.31%)
Spread: 0.10 (1.176%)
Open: 8.45
High: 8.56
Low: 8.20
Prev. Close: 8.66
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Meatable completes EUR35M Series B Financing Round

8 Aug 2023 09:05

RNS Number : 6413I
Agronomics Limited
08 August 2023
 

8 August 2023

Agronomics Limited

("Agronomics" or the "Company")

Meatable Announces Successful €35 Million Series B Financing Round

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture, is pleased to announce it has invested €4 million (the "Subscription") as part of Meatable's €35 million Series B financing round. The funding round was co-led alongside New Agrarian Company Limited ("New Agrarian").

Agronomics first invested €2 million in Meatable B.V. ("Meatable") in December 2019, followed by an additional €1 million in June 2020, €2 million in February 2021 and €195k via a secondary transaction in May 2021. Subject to audit, Agronomics' investments, inclusive of the Subscription, will be carried at €14.2 million, including an unrealised gain of €5.0 million and represents a gross IRR of 22.31%. Agronomics now holds an equity stake of 6.7% in Meatable, with the position accounting for approximately 9% of Agronomics' 30 June 2023 Net Asset Value (as adjusted for this investment).

The successful funding round was led by Agronomics and New Agrarian and saw the Dutch impact fund, Invest-NL, join as a new investor, contributing $17 million, alongside renewed support from existing investors, including BlueYard, Bridford, MilkyWay, DSM Venturing and Taavet Hinrikus (chairman and founder of Wise).

The funding will be used to further scale Meatable's production processes and accelerate its commercial programme in target markets to deliver cultivated meat products that are price competitive with traditional meat. Starting in Singapore, Meatable's sausages and pork dumpling products will be available in selected restaurants and retailers from 2024. It is also establishing a presence in the United States and target European countries. These steps ensure Meatable can bring to life its mission to make cultivated meat available for everyone, without compromising on taste or harming animals, people or the planet.

Innovative technology to produce cultivated meat at scale

Consumer demand for meat continues to grow across the world, but this comes at a huge cost to the planet. Cultivated meat is part of the solution - a study by independent research company CE Delft found that cultivated meat can reduce the footprint of conventional beef by up to 92% for greenhouse gas emissions and 95% for land use. Investors have poured nearly US$ 900 million into the sector in 2022 alone, with the Netherlands announcing the world's largest ever-public investment into cellular agriculture last year.

To make its cultivated pork, Meatable takes one sample of cells from an animal without harming it and replicates the natural growth process of the cells using its patented opti-ox technology combined with pluripotent stem cells. This technology makes it possible for Meatable to produce real muscle and fat cells in only eight days, 30 times faster than the time it takes to rear a pig for pork on the farm. Meatable has all processes in place to be able to scale cultivated meat production affordably and provide a genuine solution to this global, pressing problem.

Taking its revolutionary cultivated meat process global

To truly make an impact, cultivated meat needs to be widely available. To address this demand, Meatable is launching its first commercial products in Singapore starting in 2024, and is currently partnering with the relevant authorities to secure regulatory approval. Meatable has already successfully held its first external tasting events in Singapore earlier in 2023, following approval from the Singapore Food Agency (SFA). In addition, it has started production of its products on the ground together with Esco Aster Pye Ltd, the first and only commercially licensed cultivated meat manufacturer in Singapore, and has begun co-development of its product range with plant-based butcher Love Handle SC.

Meatable is also working to expand its operations into the United States and across Europe. Recent regulatory developments have boosted confidence in the industry, with the USA approving two cultivated meat companies to start selling their products. Meanwhile, the Netherlands recently became the first European country to officially give the green light for companies to organise tastings.

Jim Mellon, co-founder of Agronomics, said:

"Meatable is one of the leading companies helping to transform the cultivated meat industry. With 80 billion animals slaughtered every year for meat and vast amounts of the Amazon rainforest already destroyed because of animal agriculture, there is a real need to find a solution that can provide meat at the scale needed to address a growing mass market. The latest funding round will allow Meatable to scale up production in Singapore, and soon in the US, as it moves towards commercialisation as part of its Go-to-Market strategy."

Krijn de Nood, co-founder and CEO of Meatable, said:

"We are thrilled to have the renewed support of our existing investors, including Agronomics, while welcoming Invest-NL as a new investor. This is a huge sign of confidence in the incredible quality, taste, and proven scalability of our product, especially in the current investment climate. When 14% of the world's global emissions comes from the traditional meat industry, it is clear there needs to be an alternative to reduce the harm our diets are currently causing the planet. We believe cultivated meat is the answer and we are confident we have the tools and the processes in place to make this a reality. We look forward to working closely with our investors as we enter our next growth phase and cement our position as global leaders."

Since this Subscription is considered a Substantial Transaction under AIM Rule 12, this announcement requires certain disclosures under Schedule Four. Meatable is an early-stage company with no revenues with operating costs of approximately 1.6 million per month, and total assets as at 31 December 2022 of23 million, including cash or near cash of20 million with no material liabilities.

New Agrarian, the affiliate of Agronomics, has invested 6 million, on identical terms to Agronomics for 2.86%. In aggregate, Agronomics and New Agrarian will own 9.63% of Meatable on a fully diluted basis and have the right to a board seat following the close of the financing round.

About Meatable

Meatable is an innovative, Dutch food company, aiming to deliver, at scale, the new natural, cultivated meat that looks like, tastes like, and has the nutritional profile of traditional meat. Its proprietary opti-ox technology [is designed to enable] Meatable to produce meat rapidly, sustainably, and without harming animals. Founded in 2018 by Krijn de Nood (CEO), Daan Luining (CTO), and Dr. Mark Kotter (principal inventor of opti-ox technology), Meatable has brought together a team of close to 100 experts with unique knowledge in fields including molecular biology, chemistry, tissue engineering, bioprocess development, food safety, and food science to create the new natural meat. Follow Meatable: LinkedIn, Twitter, Instagram, Facebook.

About Agronomics

Agronomics is the leading listed venture capital firm with a focus on cellular agriculture. The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

About Invest-NL

Invest-NL serves as the Dutch National Promotional Institution. As a leading impact investor, its core mission is to facilitate financing for ventures that may initially seem challenging to fund. By working in collaboration with diverse stakeholders, including financiers, investors, and development specialists from both the public and private sectors, Invest-NL actively tackles significant societal challenges. These encompass the transition towards a carbon-neutral and circular economy, promoting affordable and accessible healthcare, and fostering advancements in deep tech innovations.

 

About Cellular Agriculture

 

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still, less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUPURUPWURR
Date   Source Headline
4th Dec 20197:00 amRNSUpdate on Placing and Final Results
11th Nov 20197:00 amRNSProposed Fundraise
29th Oct 20197:00 amRNSInvestment in Shiok Meats Pte. Ltd.
22nd Oct 20192:00 pmRNSCompany Newsletter
17th Oct 20197:00 amRNSInvestment in VitroLabs Inc
15th Oct 20197:00 amRNSInvestment in Rebellyous Foods
8th Oct 20197:00 amRNSNet Asset Value(s)
23rd Sep 20191:00 pmRNSAIM Rule 17 Notification
12th Sep 20197:00 amRNSInvestee Company Update
9th Sep 201911:55 amRNSHolding(s) in Company
5th Sep 20197:00 amRNSSeed Investment in Bond Pets LLC
29th Aug 20197:00 amRNSAgronomics Participates in BlueNalu Fund Raise
28th Aug 20199:42 amRNSNew website launched
27th Aug 20191:21 pmRNSInvestee company Update: Blue Nalu, Inc
12th Aug 201912:51 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNet Asset Value(s)
29th Jul 20197:00 amRNSInvestment in Simply Foods, Inc. (New Age Meats)
5th Jul 20194:40 pmRNSSecond Price Monitoring Extn
5th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 201912:58 pmRNSResult of Meeting
17th Jun 20192:05 pmRNSSecond Price Monitoring Extn
17th Jun 20192:00 pmRNSPrice Monitoring Extension
17th Jun 201911:00 amRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSEquity Fundraise Closes at £4.5 million
10th Jun 20197:00 amRNSProposed Equity Fundraise
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.